SHR-A1811 plus other therapies for advanced HER2+ tumors
Part of Cancer clinical trials.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of advanced cancer (solid tumor) that has spread or cannot be removed with surgery, and your tumor has HER2 protein or a HER2 gene change.
- You are willing to provide a tumor sample (either from a previous biopsy or a new one) within the last year.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You have not had certain other cancer treatments or conditions, like untreated brain metastases, serious lung disease, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SHR-1811, combined with carboplatin for advanced breast cancer that has HER2 expression (including low levels). It is for people who have already tried standard treatments and their cancer has spread or cannot be removed by surgery.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
This trial combines two targeted medications (SHR-A1811 and pyrotinib) for people with HER2-positive breast cancer that has spread or cannot be removed with surgery. It is for those whose cancer has stopped responding to previous HER2-targeted therapies or chemotherapy.
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
Hear when a new HER2-expressing Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.